Advertisement

Experimental Designs for the Study of Receptor–Receptor Interactions

  • Dennis PaulEmail author
Protocol
Part of the Neuromethods book series (NM, volume 60)

Abstract

With the rise of interest in receptor–receptor interaction research, optimization of experimental designs to study the nature of interactions has become increasingly important. In this chapter, traditional experimental designs and their associated statistics are reviewed, and their theoretical and practical limitations are described. The logic and theory behind isobolographic analysis is explained and their practical use is also described. As more and more receptor–receptor interactions are recognized with the use of two or more GPCR drugs, advances in the analysis of the type presented here will become more significant and important for clinical pharmacotherapy.

Key words

Experimental design Isobolographic analysis Synergism Additivity Interference 

References

  1. 1.
    Tallarida RJ (2006) An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319:1–7PubMedCrossRefGoogle Scholar
  2. 2.
    Loewe S (1953) The problem of synergism and antagonism of combined drugs. Arzneim-Forsch 3:385–390Google Scholar
  3. 3.
    Tallarida RJ, Porreca F, Cowan A (1986) Statistical analysis of drug-drug and site-site interactions with isobolograms. Life Sci. 45:947–961CrossRefGoogle Scholar
  4. 4.
    Tallarida RJ (1992) Statistical analysis of drug combinations for synergism. Pain 49:93–97PubMedCrossRefGoogle Scholar
  5. 5.
    Tallarida RJ, Murray RB (1987) Manual of Pharmacologic Calculation with Computer Programs, 2nd ed, Springer, New YorkGoogle Scholar
  6. 6.
    Tallarida RJ, Stone DJ, Raffa RB (1997) Efficient designs for studying synergistic drug combinations. Life Sci 61:PL417–425CrossRefGoogle Scholar
  7. 7.
    Stone LS, MacMillan LB, Kitto KF et al (1997) The α2a adrenergic receptor subtype mediates spinal analgesia evoked by α2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 17:7157–7165PubMedGoogle Scholar
  8. 8.
    Tallarida RJ, Stone DJ Jr, McCary JD et al (1999) Response surface analysis of synergism between morphine and clonidine. J Pharmacol Exp Ther 289:8–13PubMedGoogle Scholar
  9. 9.
    Grabovsky, Y, Tallarida, RJ (2004) Isobolographic analysis for combinations of a full and partial agonist: Curved isoboles. J Pharmacol Exp Ther 310:981–986PubMedCrossRefGoogle Scholar
  10. 10.
    Overland AC, Kitto KF, Chabot-Doré AJ et al (2009) Protein kinase C mediates the synergistic interaction between agonists acting at α2-adrenergic and delta opioid receptors in spinal cord. J Neurosci 29:13264–13273PubMedCrossRefGoogle Scholar
  11. 11.
    Ossipov MH, Lopez Y, Bian D et al (1997) Synergistic antinociceptive interactions between alpha 2-adrenergic receptor antagonists. Anesthesiology 86:1–9CrossRefGoogle Scholar
  12. 12.
    Tallarida RJ (2002) The interaction index: a measure of drug synergism. Pain 98:163–168.PubMedCrossRefGoogle Scholar
  13. 13.
    Brodkin J, Shannon HE (2000) Communicating synergism in drug combination studies. Arzneimittelforschung. 2000 50:765–767PubMedGoogle Scholar
  14. 14.
    Gershwin ME, Smith NT (1973) Interaction between drugs using three-dimensional isobolographic interpretation. Arch Int Pharmacodyn Ther. 201:154–161PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Pharmacology and Experimental TherapeuticsLouisiana State University Health Sciences CenterNew OrleansUSA

Personalised recommendations